1. Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients.
- Author
-
Imberti, Luisa, Scarsi, Mirko, Zanotti, Cinzia, Chiarini, Marco, Bertoli, Diego, Tincani, Angela, and Airò, Paolo
- Subjects
- *
T cells , *LYMPHOCYTES , *RHEUMATOID arthritis , *ABATACEPT , *AUTOIMMUNE diseases , *CHIMERIC proteins - Abstract
Background CD28neg T cells, which display functional characteristic of oligoclonally expanded cytotoxic memory T lymphocytes, are believed to be pathologically relevant in rheumatoid arthritis manifestation. The CD28 co-stimulation blockade by abatacept can prevent the generation of CD28neg T-cell populations in these patients. Methods Samples were obtained before and after 12 months of abatacept therapy. T-cell phenotype and T-cell receptor diversity were evaluated by flow cytometry and complementaritydetermining region-3 spectratyping, respectively, while telomerase reverse-transcriptase gene level was measured by real-time PCR. Results Abatacept induces a decrease of the percentage and number of CD4+CD28neg T cells and a reduction of T-cell repertoire restrictions; these features are directly correlated. Thymic output and telomerase activity are not modified by the therapy. Conclusions Abatacept-induced decrease of peripheral T-cell repertoire restrictions can due to a reduced generation of senescent, chronically stimulated CD4+CD28neg T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF